Predicting response after [166Ho]-radioembolization in patients with neuroendocrine tumor liver metastases using neutrophil-to-lymphocyte and thrombocyte-to-lymphocyte ratios

#3107

Introduction: Response after treatment with [166Ho]-radioembolization is difficult to predict in patients with NET. Neutrophil-to-lymphocyte ratio (NLR) and thrombocyte-to-lymphocyte ratio (TLR) have been described as prognosticators for response.

Aim(s): The aim of this study was to analyse the prognostic value of pre-treatment and post-treatment NLR and TLR on objective response.

Materials and methods: Data from the prospective clinical HEPAR PLuS study was used in this study. NLR and TLR were calculated at baseline (i.e. prior to [166Ho]-radioembolization), at three weeks, and at six weeks follow-up (FU), by dividing the absolute neutrophil or thrombocyte count by the lymphocyte count. Logistic regression and Cox Proportional Hazards regression were performed to test the prognostic value of absolute NLR and TLR at baseline, and change in NLR and TLR after [166Ho]-radioembolization on response and overall survival.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Ebbers S

Authors: Ebbers S, Brabander T, Tesselaar M, Hofland J, Barentsz M,

Keywords: PRRT, NET, neuroendocrine tumor, neuroendocrine neoplasm, lutetium-177-dotatate, radioembolization, holmium-166, objective response, NLR, TLR,